Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery

We are  pleased to announce the successful conclusion of an independent feasibility study with Evonik Canada Inc., part of Evonik Industries, one of the world´s leading specialty chemicals companies. The study aimed to evaluate the capabilities of LEON’s proprietary FR-JET technology and confirmed its exceptional performance in manufacturing nanoparticles for drug delivery.

 

READ MORE HERE

 

LEON : Enabling Nano Now

About LEON

Based in Planegg/Munich, leon-nanodrugs GmbH is a pharmatech company specializing in the development and commercialization of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanoparticles, such as lipid nanoparticles (LNPs).

The company leverages its proprietary FR-JET®  technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and commercial production, and the company further supports its clients by offering formulation and process development services.

LEON’s platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs to capitalize on advancements in advanced therapies.

For general information and enquiries please email info@leon-nanodrugs.com